Novo Nordisk gets 2.0 mg Ozempic dose approved in US

The pharmaceutical firm expects to launch 2.0 mg doses of Ozempic in the US during the second quarter of 2022.

Photo: Novo Nordisk / PR

The US Food and Drug Administration (FDA) has approved Ozempic in a 2.0 mg dose for the treatment of adults with type 2 diabetes.

Ozempic, which is a GLP-1 analog administered once a week, is therefore now approved in the US in 0.5, 1.0 and 2.0 mg doses.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs